Poolbeg Pharma #POLB – Admission to AIM and First day of trading

Poolbeg Pharma (AIM: POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model , is pleased to announce that admission of its entire issued share capital to trading on the AIM market of the London Stock Exchange will become effective and dealings will commence at 8.00 a.m. today under the ticker […]

ECR Minerals #ECR – Resignation of Consultant Stephen Clayson

ECR Minerals plc (LON: ECR), the gold exploration and development company focused on Australia, announces that Stephen Clayson, long standing consultant and former ECR CEO and Director until August 2016, has resigned with immediate effect. Stephen Clayson was instrumental in developing and progressing ECR’s interest in the Danglay gold project; with a 43-101 compliant gold […]

Ananda Developments #ANA – Issue of Equity

Ananda announces that 96,890 ordinary shares of 0.2p each in the Company (“Ordinary Shares”) have been issued following the exercise of warrants at 0.45p per share. The proceeds receivable by the Company will be used for general working capital purposes. Application will be made for the new Ordinary Shares to be admitted to trading on […]

Power Metal Resources #POW Signs an Agreement to Earn-in to a 100% Interest in Lithium Exploration Properties in Quebec, Canada

Power Metal Resources plc (LON:POW), the AIM listed metals exploration and development company, is pleased to announce that the Company’s 100% owned Canadian subsidiary Power Metal Resources Canada Inc. (“Power Metal Canada”), has signed an earn-in agreement (the “Earn-in Agreement”) through which it may acquire a 100% interest in two Canadian lithium pegmatite exploration properties […]

Ananda Developments #ANA – Issue of Convertible Loan Notes

Ananda announces that the Company has raised £350,000 (gross) and received firm commitments for a further £200,000 (gross) of  convertible loan notes  (“CLNs”). The CLNs will be convertible into ordinary shares in the Company (“Ordinary Shares”) at a price of 1p per share and will have a  fixed life of 2 years. The CLNs bear […]

Open Orphan #ORPH – AIM Schedule 1 update by Poolbeg Pharma plc

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , notes the AIM Schedule One released in relation to Poolbeg Pharma plc (“Poolbeg”) this morning, 14 July 2021 at 8.00 a.m. updating on Poolbeg’s admission to AIM […]